These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12754630)

  • 21. Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy.
    Yu JR; Yang XJ; Yang WL; Gao Y; Zhang Q
    Scand J Gastroenterol; 2007 Sep; 42(9):1138-40. PubMed ID: 17710683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances.
    Voelzke BB; Sakamoto K; Hantel A; Paner GP; Kash J; Waters WB; Campbell SC
    Urology; 2002 Aug; 60(2):218-22. PubMed ID: 12137812
    [No Abstract]   [Full Text] [Related]  

  • 23. Downstaging of an advanced gastrointestinal stromal tumor by neoadjuvant imatinib.
    de Vos tot Nederveen Cappel RJ; van Hillegersberg R; Rodenhuis S; Peterse JL; van Coevorden F
    Dig Surg; 2004; 21(1):77-9. PubMed ID: 14967958
    [No Abstract]   [Full Text] [Related]  

  • 24. Haemoperitoneum as an indicator of GIST.
    de Juan Ferré A; Gutiérrez L; Garicano F; Malaxetxebarria S; Fernández F
    Anticancer Drugs; 2012 Jun; 23 Suppl():S10-2. PubMed ID: 22739665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer treatment. New drugs, new hope.
    Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA; Verweij J
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report.
    Rediti M; Pellegrini E; Molinara E; Cerullo C; Fonte C; Lunghi A; Iori A; Neri B
    Anticancer Res; 2014 Feb; 34(2):905-7. PubMed ID: 24511030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors.
    DeCaprio JA; Duensing A
    Curr Opin Oncol; 2014 Jul; 26(4):415-21. PubMed ID: 24840522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
    Antoch G; Kanja J; Bauer S; Kuehl H; Renzing-Koehler K; Schuette J; Bockisch A; Debatin JF; Freudenberg LS
    J Nucl Med; 2004 Mar; 45(3):357-65. PubMed ID: 15001674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.
    Bongiovanni A; Ricci M; Riva N; Calpona S; Oboldi D; Pieri F; Cavaliere D; Mercatali L; Liverani C; La Manna F; De Vita A; Foca F; Gunelli E; Amadori D; Ibrahim T
    Future Oncol; 2014 Dec; 10(15):2423-7. PubMed ID: 25525851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Gold JS; Dematteo RP
    Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy of imatinib for treatment of metastatic GIST.
    Patel S
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
    Gao X; Shen K; Wang C; Ling J; Wang H; Fang Y; Shi Y; Hou Y; Qin J; Sun Y; Qin X
    Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):72-5. PubMed ID: 24217767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GIST 1, chemotherapy 0, with a brand new hitter up next.
    Demetri GD
    Cancer Invest; 2002; 20(5-6):853-4. PubMed ID: 12197245
    [No Abstract]   [Full Text] [Related]  

  • 39. [The effect of imatinib for gastrointestinal tumor].
    Mizunuma N
    Nihon Rinsho; 2004 Jul; 62(7):1332-6. PubMed ID: 15283152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.
    Salazar M; Barata A; André S; Venâncio J; Francisco I; Cravo M; Nobre-Leitão C
    Gut; 2006 Apr; 55(4):585-6. PubMed ID: 16531543
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.